Tmunity has two development-stage oncology programs that will enter the clinic over the next 12 months.
TMUN ONC 001:PSMA CAR for prostate cancer
TMUN ONC 002:NY-ESO1 CRISPR edited PD-1 knockout TCR. This will be the first gene-edited TCR to enter human clinical studies in the United States, with initiation planned for 2H 2017. Tmunity plans to evaluate three potential indications in myeloma, sarcoma and melanoma.
TMUN ONC 003:GFRa4 CAR for medullary thyroid cancer
TMUN ONC 004:MUC-1 CAR for solid tumors